CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

GSK Drops Chronic Cough Drug as Shares Fall 4.5%

Negative
AI Analysis

Summary

GSK discontinued its chronic cough drug program, resulting in a 4.5% decline in share price. The specific drug name and development stage were not disclosed in the article.

Outcome Details

Drug program discontinued

Importance:4/10
Sentiment:
-0.70
drug_discontinuationstock_declineR&D
Related Companies

Read the original article

Published by yahoo_finance on July 20, 2026 4:44 PM

Read Original